Swiss National Bank Sells 800 Shares of Collegium Pharmaceutical, Inc. $COLL

Swiss National Bank reduced its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report) by 1.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,500 shares of the specialty pharmaceutical company’s stock after selling 800 shares during the quarter. Swiss National Bank owned 0.19% of Collegium Pharmaceutical worth $1,866,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after acquiring an additional 339 shares during the last quarter. SummerHaven Investment Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 1.9% in the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $727,000 after purchasing an additional 448 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 4.5% in the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company’s stock worth $326,000 after purchasing an additional 477 shares in the last quarter. Virtus Fund Advisers LLC boosted its holdings in shares of Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Collegium Pharmaceutical by 4.2% in the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company’s stock worth $426,000 after purchasing an additional 578 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on COLL shares. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. HC Wainwright upgraded Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price objective for the company in a report on Monday, August 11th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Buy” and an average target price of $42.33.

View Our Latest Stock Report on Collegium Pharmaceutical

Collegium Pharmaceutical Trading Down 1.0%

Shares of COLL stock opened at $39.11 on Friday. The stock has a market capitalization of $1.23 billion, a PE ratio of 37.61 and a beta of 0.68. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The business has a 50-day moving average of $32.42 and a 200 day moving average of $30.05. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10.

Collegium Pharmaceutical declared that its board has approved a share repurchase plan on Monday, July 7th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 11,659 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the completion of the transaction, the director owned 23,129 shares of the company’s stock, valued at $794,712.44. This represents a 33.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 16,389 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $38.21, for a total value of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $3,959,052.73. The trade was a 13.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,915 shares of company stock worth $1,614,825 in the last ninety days. 2.51% of the stock is owned by company insiders.

Collegium Pharmaceutical Company Profile

(Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Read More

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.